Valuation Spero Therapeutics, Inc. Börse Stuttgart
Stocks
2HA
US84833T1034
Biotechnology & Medical Research
|
Market Closed -
Börse Stuttgart
15:55:14 2026-10-09 EDT
|
5-day change | 1st Jan Change | ||
| 1.056 EUR | +5.28% |
|
+0.67% | -44.60% |
| 08-12 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 69.88 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -46.77% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 69.88 | 69.88 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -46.77% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -2.07x | -11.4x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 28.3x | 1.67x | 0.75x | 1.17x | - | 271x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 271x | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | - | -1.91x | -1.27x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.58 | -0.105 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 18.26 | 53.51 | 103.8 | 47.98 | - | 0.258 | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT 1 | -87.97 | -42.2 | 21.48 | -73.36 | - | -36.66 | -55 |
| Net income 1 | -89.76 | -46.42 | 22.81 | -68.57 | - | -33.46 | -51.5 |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.200 | 1.200 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/13/24 | 3/27/25 | 3/26/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.5x | 7.3x | 14.66x | 1.45% | 70.61B | |
| 27.46x | 7.51x | 23.56x | 0.05% | 51.01B | |
| 33.37x | 6x | 17.96x | 0.97% | 48.1B | |
| 33.47x | 3.25x | 14.03x | -.--% | 42.78B | |
| -19.64x | 203.45x | -20.92x | -.--% | 40.67B | |
| 46.95x | 5.34x | 29.33x | -.--% | 40.3B | |
| 27.18x | 7.73x | 20.09x | 0.42% | 30.59B | |
| 32.53x | 6.94x | 18.03x | -.--% | 28.16B | |
| -14.69x | 5.97x | -7.21x | -.--% | 24.36B | |
| Average | 20.79x | 28.17x | 12.17x | 0.32% | 41.84B | |
| Weighted average by Cap. | 22.22x | 27.60x | 13.22x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- 2HA Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
